Navalit (Doxylamine Hydrogen Succinate, Pyridoxine Hydrochloride)

Doxylamine hydrogen succinate and pyridoxine hydrochloride, the active ingredients in Navalit, are an antihistamine (H1 antagonist) and vitamin B6 presented as an oral formulation for use in pregnant women. It alleviates nausea and vomiting of pregnancy (morning sickness). GNH USA supplies Navalit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Navalit is used to manage nausea and vomiting associated with pregnancy, acting on the vestibular and neurotransmitter pathways that trigger these symptoms.

Nausea and vomiting of pregnancy: reduces frequency and severity of morning sickness. Hyperemesis gravidarum: provides symptomatic relief when conventional measures are insufficient. Pregnancy‑related nausea: helps improve maternal comfort and hydration.

Navalit may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Drowsiness or sedation - Dry mouth - Constipation - Blurred vision - Dizziness - Headache

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis, angioedema) - Skin reactions such as Stevens‑Johnson syndrome - Hallucinations or confusion - Seizures (rare)

Before initiating Navalit, consider patient‑specific factors and potential risks. - Medical history review: assess for glaucoma, asthma, or urinary retention. - Alcohol and CNS depressants: avoid concurrent use to reduce excessive sedation. - Sedating drugs: monitor closely when combined with benzodiazepines or opioids. - Allergies: discontinue if signs of hypersensitivity appear. - Pregnancy monitoring: use under medical supervision throughout gestation. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Navalit can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Other sedating antihistamines or CNS depressants: may cause profound drowsiness. - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Anticholinergic agents: increase risk of dry mouth and urinary retention.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible additive hypotensive effect. - Selective serotonin reuptake inhibitors (SSRIs): monitor for serotonin syndrome. - Oral contraceptives: may reduce contraceptive efficacy, advise backup method.